Cardiovascular diseases Trials in Beijing, China
Conditions / Cardiovascular diseases / Beijing, China
Clinical trials for Cardiovascular diseases investigate a range of treatment strategies and patient populations.
54 total trials for this combination
Showing top 10 of 54 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING | — |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING | — |
| NCT06543706 | Metabolic Syndrome and Related Diseases in Healthcare Workers | COMPLETED | — |
| NCT01471522 | International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA) | COMPLETED | NA |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | COMPLETED | — |
| NCT03072797 | Beijing Hospital Atherosclerosis Study | UNKNOWN | — |
| NCT03683186 | A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label Extension | ENROLLING_BY_INVITATION | PHASE3 |
| NCT03626688 | A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH Patients | COMPLETED | — |
| NCT07064473 | EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease | RECRUITING | — |
| NCT00153101 | Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo. | COMPLETED | PHASE4 |